Position in JANX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,306,238
+$582,829 QoQ
Shares Held
93,974
+79.3% QoQ
Ownership
0.154%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Aquatic Capital Management LLC holds $123,092,373 across 91 Biotechnology names. JANX ranks #30 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
147,379 | $11,066,689 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
31,061 | $10,277,153 | |
| 3 | EXEL |
Exelixis, Inc.
|
194,571 | $8,345,150 | |
| 4 | RPRX |
Royalty Pharma plc
|
127,227 | $6,103,079 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
80,227 | $5,030,232 | |
| 6 | CYTK |
Cytokinetics Inc
|
72,478 | $4,777,024 | |
| 7 | XENE |
Xenon Pharmaceuticals Inc.
|
79,199 | $4,605,421 | |
| 8 | NKTR |
Nektar Therapeutics
|
57,014 | $4,102,157 |
All Filings in JANX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,306,238 | 93,974 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $723,409 | 52,421 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | $993,923 | 43,027 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,686,663 | 62,469 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $329,592 | 6,156 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||